$REGN (Regeneron Pharmaceuticals, Inc.)

$REGN {{ '2016-05-05T11:27:05+0000' | timeago}} • Announcement

$REGN posted net product sales of $784MM in 1Q16 compared to $545MM in 1Q15. EYLEA net product sales in the United States were $781MM in 1Q16, up 44% compared to 1Q15. Net sales of Praluent were $13MM.

$REGN {{ '2017-09-18T10:59:56+0000' | timeago}} • Announcement

Pharma company $REGN and healthcare firm $SNY said a study showed that Dupixent, which is indicated for the treatment of atopic dermatitis, significantly improved overall disease severity. It also met the primary end point - the proportion of patients that achieved a 75% or greater improvement at 16 weeks from baseline.

$REGN {{ '2017-09-11T11:11:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma. The investigational dupilumab lowered severe asthma attacks and improved lung function. The companies plan to submit a Supplemental Biologics License Application (sBLA) to the U.S. FDA by the end of this year.

$REGN {{ '2017-08-14T13:55:04+0000' | timeago}} • Announcement

$REGN has announced that it would discontinue developing its drug to prevent respiratory syncytial virus (RSV) infections in infants. Its Phase 3 study evaluating suptavumab, an antibody to RSV, did not meet its primary endpoint of preventing the infection following which the company planned to stop further clinical development of this antibody.

$REGN {{ '2017-08-03T14:59:22+0000' | timeago}} • Webcast

The US sales of $REGN’s flagship macular degeneration drug EYLEA rose 10% YoY in the first half of 2017, driven by higher demand and increased market share. Regeneron expects to fully utilize the $130MM annual funding from its collaborator Sanofi, under an antibody discovery agreement, by the end of the third quarter.

$REGN {{ '2017-08-03T14:30:54+0000' | timeago}} • Webcast

$REGN said its arthritis drug Kevzara received approval from the US FDA and the European Commission in 2Q17. In the second half of this year, topline data from phase-2 studies on wet age related macular degeneration and diabetic macular edema are expected to be published. Results from study on a cardiovascular drug will be released in early 2018.

$REGN {{ '2017-08-03T12:12:28+0000' | timeago}} • Announcement

$REGN raised sales growth forecast for FY17 to 10% from the earlier outlook of single-digit increase. The company anticipates non-GAAP R&D expenses between $925MM and $965MM. The guidance of non-GAAP selling, general and administrative expenses has been raised to the range of $1.12-$1.16Bil. Regeneron sees effective tax rate of 27-31% for the year.

$REGN {{ '2017-08-03T11:54:57+0000' | timeago}} • Announcement

Earnings of pharmaceuticals company $REGN nearly doubled to $388MM in 2Q17 as strong sales of its leading products, including the EYLEA injection, lifted revenues by 21% to $1.47Bil. EPS grew 48%YoY to $3.34, while non-GAAP earnings advanced to $4.17 per share. The higher revenues resulted in an 88% gain in operating income.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$REGN {{ '2017-06-22T14:02:42+0000' | timeago}} • Announcement

$REGN provided details of the royalty it receives on any sales of canakinumab (ACZ885). $REGN received a royalty on worldwide net sales of canakinumab; the royalty rate starts at 4% and reaches 15% when canakinumab annual sales exceed $1.5Bil.

$REGN {{ '2017-06-12T10:58:03+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes. In the studies, Praluent, when administered on top of maximally tolerated doses of statins, significantly reduced low-density lipoprotein cholesterol, the primary endpoint of the study.

$REGN {{ '2017-06-05T12:01:45+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive preliminary results with investigational REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). CSCC is the second most common type of skin cancer in the U.S.

$REGN {{ '2017-05-23T12:31:01+0000' | timeago}} • Announcement

$REGN said the U.S. Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease modifying antirheumatic drugs, such as methotrexate (MTX).

$REGN {{ '2017-05-08T12:57:32+0000' | timeago}} • Announcement

$REGN and SillaJen, Inc. announced a new clinical and supply agreement for a Phase 1b dose-escalation study in renal cell carcinoma. Under the terms of the agreement, the trial will be solely conducted and funded by SillaJen based upon a mutually developed study design and $REGN will provide REGN2810.

$REGN {{ '2017-05-08T12:56:18+0000' | timeago}} • Announcement

$REGN and SillaJen, Inc. announced a new clinical and supply agreement for a Phase 1b dose-escalation study in renal cell carcinoma. The open-label trial is expected to begin later this year, and is designed to evaulate the safety and efficacy of REGN2810 in combination with Pexa-Vec compared to treatment with REGN2810 as monotherapy.

$REGN {{ '2017-05-08T12:38:36+0000' | timeago}} • Announcement

$REGN and $INO announced a clinical study agreement for a phase 1b/2a immuno-oncology trial for glioblastoma combination therapy. Glioblastoma is the most common and aggressive type of brain cancer. The open-label trial is expected to begin later this year.

$REGN {{ '2017-05-04T19:05:59+0000' | timeago}} • Webcast

$REGN said that the FDA's advisory group had pushed the company to start a trial for younger populations even sooner than one might normally in the development program. The company added that it will move towards younger age groups steadily.

$REGN {{ '2017-05-04T12:17:34+0000' | timeago}} • Infographic

$REGN Regeneron Pharmaceuticals Earnings AlphaGraphics: Q1 2017 highlights

$REGN {{ '2017-05-04T11:15:52+0000' | timeago}} • Announcement

$REGN now sees FY17 capex at $300-350MM, with an effective tax rate of 32-38%. EYLEA U.S. net product sales are expected to grow in single-digit percentage over last year. Sanofi reimbursement of Regeneron commercialization-related expenses ae expected at $385-425MM, while non-GAAP SG&A is projected at $1.14-$1.20Bil for the year.

$REGN {{ '2017-05-04T11:07:43+0000' | timeago}} • Announcement

Total revenues of $REGN rose 10% to $1.32Bil in 1Q17, as the pharma company posted a 38% jump in net income of $249MM from last year's $181MM. Earnings hiked 36% to $2.16 per diluted share, as its EYLEA U.S. net product sales saw a 9% surge to $854MM for the quarter.

$REGN {{ '2017-04-28T16:21:45+0000' | timeago}} • Announcement

$REGN and Sanofi said the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab) as a Class I response with a two month review timeline. Kevzara will treat moderately to severely active rheumatoid arthritis (RA).

Recent Transcripts

AMS (American Shared Hospital Services)
Thursday, August 10 2017 - 7:00pm
NVO (Novo Nordisk A/S)
Thursday, August 10 2017 - 12:15pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
NVO (Novo Nordisk A/S)
Wednesday, August 9 2017 - 11:00am
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
IRIX (IRIDEX Corporation)
Thursday, August 3 2017 - 9:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
IMGN (ImmunoGen, Inc.)
Friday, July 28 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like